After several pharmaceutical companies agreed to halt drug price increases in 2018 after receiving pressure from the Trump administration, the industry has kicked off 2019 with price increases on more than 250 prescription drugs.
After several pharmaceutical companies agreed to halt drug price increases in 2018 after receiving pressure from the Trump administration, the industry has kicked off 2019 with price increases on more than 250 prescription drugs.
According to an analysis from Rx Savings Solutions, reports Reuters, dozens of drugs produced by companies such as Allergan and Hikma Pharmaceuticals saw average price increases of nearly 6.3% in the new year, with Allergan raising list prices on 50 plus drugs, and more than half of these by 9.5%. Similarly, Hikma raised the price of its morphine product by 10%, and of its blood pressure medication, enalaprilat, by 30%.
However, the overall number of price increases was down by around one-third from 2018, when, according to the analysis, drug makers raised prices on more than 400 medications.
Though the price hikes are off to a more cautious start industry-wide than years past, Michael Rea, founder and chief executive of Rx Savings Solutions, told Bloomberg that he believes that many pharma companies will wait until after the first week of January to institute most price hikes, as, historically speaking, that is when most pricing activity has taken place. “People will play the game differently to avoid the spotlight and fly under the radar,” he indicated.
One company that has already instituted price increases is reference adalimumab developer AbbVie. The drug maker has increased the price of Humira, the top-selling drug worldwide that does not face US biosimilar competition until 2023, by 6.2%. Though earnings for the full year of 2018 have not yet been released, the drug is estimated to have earned nearly $20 billion in sales.
In mid-2018, Pfizer was the first to announce a 2018 price freeze on its drug products, followed by other large drug companies such as Merck, Roche, and Novartis. However, when announced, these price freezes faced public scrutiny as to whether patients would actually realize any benefit. Several analysts shared their doubts, explaining that the freeze was enacted after certain companies already completed their price hikes, or companies had lowered the prices on drugs that made up less than 0.1% of total sales.
The Trump Administration has focused on lowering drug prices and has proposed numerous policy changes in an effort to address the problem. However, propositions including the American Patients First blueprint, and the more recently announced International Pricing Index are still in their early stages and require legal and congressional input before patients’ wallets could feel any relief from these efforts.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.